Online inquiry

IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11648MR)

This product GTTS-WQ11648MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets LAG3&PDCD1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002286.6; NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3902; 5133
UniProt ID P18627; Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ11648MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ5140MR IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CAN-04
GTTS-WQ4533MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-936558
GTTS-WQ12828MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ONC-005
GTTS-WQ5392MR IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CD58-Fc
GTTS-WQ9702MR IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA JNJ-64304500
GTTS-WQ8199MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA hLIV22
GTTS-WQ10325MR IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LJM716
GTTS-WQ11741MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MK-0646
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW